The effect of different doses of infusion solutions on the endothelial glycocalyx layer in patients who underwent laparoscopic cholecystectomy

Phase 4

• Registration Number: DRKS00007904
• Lead Sponsor: Karlovac General Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-04-15
• Study Completion: 2017-11-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Patients with anesthesiologic risk I and II according to American Society of Anesthesiologists (ASA). ASA I status includes completely healthy patients and ASA II status includes patients with well regulated chronic dsseases such as arterial hypertension. Patients between 18 and 75 years old, male or female.

Exclusion Criteria

The patients younger than 18 and older than 75 years of age will be excluded and those with a local or systemic inflammatory and immune disease, diabetes, COPD, acute heart failure, acute and chronic renal failure, hematologic and malignant diseases, atherosclerotic disease, stroke and subarachnoid haemorrhageliver damage and patients that will receive blood products during surgery as well as patients who will develop acute renal failure during surgery or will become hypotensive with organ hypoperfusion and ischemia.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary objective of this study was to examine the effects of various volumes of infusion solutions on patients’ concentrations of syndecan-1, heparan sulfate, and hyaluronic acid, the main components of the endothelial glycocalyx, in patients undergoing laparoscopic cholecystectomy. We also measured patients’ concentrations of ANP and how they correlated with changes in the main glycocalyx components. <br> The study included subjects (patients) with gallstones who underwent surgical procedure of laparoscopic cholecystectomy. Laboratory samples were taken preoperative, during operation (after the establishment of pneumoperitoneum), immediately after the operation and 6 h after the operation.